WO2007056527A3 - Diagnostic and therapeutic methods and agents - Google Patents

Diagnostic and therapeutic methods and agents Download PDF

Info

Publication number
WO2007056527A3
WO2007056527A3 PCT/US2006/043665 US2006043665W WO2007056527A3 WO 2007056527 A3 WO2007056527 A3 WO 2007056527A3 US 2006043665 W US2006043665 W US 2006043665W WO 2007056527 A3 WO2007056527 A3 WO 2007056527A3
Authority
WO
WIPO (PCT)
Prior art keywords
hbv
agents
diagnostic
therapeutic methods
infection
Prior art date
Application number
PCT/US2006/043665
Other languages
French (fr)
Other versions
WO2007056527A2 (en
Inventor
George Ka-Kit Lau
Chee-Kin Hui
Hai Ying Zhang
Original Assignee
Cheng Si Yuan China Internatio
George Ka-Kit Lau
Chee-Kin Hui
Hai Ying Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheng Si Yuan China Internatio, George Ka-Kit Lau, Chee-Kin Hui, Hai Ying Zhang filed Critical Cheng Si Yuan China Internatio
Priority to AU2006311462A priority Critical patent/AU2006311462A1/en
Priority to EP06837256A priority patent/EP1951914A4/en
Publication of WO2007056527A2 publication Critical patent/WO2007056527A2/en
Publication of WO2007056527A3 publication Critical patent/WO2007056527A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present invention relates generally to the fields of therapy and diagnosis of Hepatitis B virus (HBV) infection in animal species including humans. The present invention further provides compounds and compositions useful in the treatment of HBV infection in animal species such as humans including agents which facilitate clearance of HBV and in particular chronic HBV infection.
PCT/US2006/043665 2005-11-09 2006-11-09 Diagnostic and therapeutic methods and agents WO2007056527A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2006311462A AU2006311462A1 (en) 2005-11-09 2006-11-09 Diagnostic and therapeutic methods and agents
EP06837256A EP1951914A4 (en) 2005-11-09 2006-11-09 Diagnostic and therapeutic methods and agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73548005P 2005-11-09 2005-11-09
US60/735,480 2005-11-09

Publications (2)

Publication Number Publication Date
WO2007056527A2 WO2007056527A2 (en) 2007-05-18
WO2007056527A3 true WO2007056527A3 (en) 2009-05-14

Family

ID=38023993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043665 WO2007056527A2 (en) 2005-11-09 2006-11-09 Diagnostic and therapeutic methods and agents

Country Status (3)

Country Link
EP (1) EP1951914A4 (en)
AU (1) AU2006311462A1 (en)
WO (1) WO2007056527A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108802383A (en) * 2018-06-21 2018-11-13 首都医科大学附属北京地坛医院 The low replicative phase pregnant and perinatal period reactivation monitoring device of hepatitis B "small three positive"

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101979557B (en) * 2010-10-28 2015-07-01 百奥迈科生物技术有限公司 SiRNA molecule and application thereof to antiviral medicaments
PE20211647A1 (en) 2015-03-16 2021-08-24 Hoffmann La Roche COMBINED TREATMENT WITH A TLR7 AGONIST AND AN INHIBITOR OF HBV CAPSIDE ASSEMBLY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230340D1 (en) * 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use
JP2007503268A (en) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー Delivery of immune response modifying compounds
NZ545536A (en) * 2003-09-05 2010-04-30 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ISOGAWA ET AL.: "Toll-like receptor signaling inhibits hepatitis B virus replication in vivo", J VIROL., vol. 79, no. 11, June 2005 (2005-06-01), pages 7269 - 7272, XP002547238 *
See also references of EP1951914A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108802383A (en) * 2018-06-21 2018-11-13 首都医科大学附属北京地坛医院 The low replicative phase pregnant and perinatal period reactivation monitoring device of hepatitis B "small three positive"
CN108802383B (en) * 2018-06-21 2021-05-11 首都医科大学附属北京地坛医院 Hepatitis B three-small positive low replication period pregnancy period reactivation monitoring equipment

Also Published As

Publication number Publication date
EP1951914A2 (en) 2008-08-06
EP1951914A4 (en) 2009-11-04
WO2007056527A2 (en) 2007-05-18
AU2006311462A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
CY1112848T1 (en) SUSPENSION VIRUS INHIBITIONS C
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
EA200601467A1 (en) MACROCYCLIC COMPOUNDS AS VIRAL REPLICATION INHIBITORS
MX2013003634A (en) Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases.
EP2567960A3 (en) Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis
WO2008106058A3 (en) Inhibitors of serine proteases
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
MA33806B1 (en) INHIBITORS OF HEPATITIS C VIRUS
WO2010001169A3 (en) Chemical compounds 251
EA201100390A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
BRPI0415373A (en) macrocyclic carboxylic acids and acylsulfonamides as hcv replication inhibitors
EA200971026A1 (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
ZA200803493B (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
EA200900154A1 (en) PHOSPHATE COMPOUNDS (VARIANTS), PHARMACEUTICAL COMPOSITION ON THEIR BASIS, METHOD OF TREATING VIRAL HEPATITIS WITH ITSELVES, THERAPEUTIC MEANS ON THEIR BASIS AND NUMBER NUMBER NUMBER OF THE FOUNDATIONS OF THE VEHICLES OF THEIR BASIC RESEARCHES CHAPTERS CHAPTER
EA200970375A1 (en) CONNECTIONS AND METHODS OF TREATMENT OF HEPATITIS C VIRUS
ATE551343T1 (en) TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
DE602008004317D1 (en) COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
HK1114876A1 (en) Arthrospira-based compositions and uses thereof
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
WO2007014943A3 (en) Therapy for neurological diseases
TW200716226A (en) Compositions comprising actinidia and methods of use thereof
IL178094A0 (en) Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions
DE602008006257D1 (en) CYCLOPROPYL-CONDENSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006311462

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006311462

Country of ref document: AU

Date of ref document: 20061109

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006837256

Country of ref document: EP